ENTRY       D03931                      Drug
NAME        Ecallantide (USAN/INN);
            Ecallantide (genetical recombination) (JAN);
            Kalbitor (TN)
PRODUCT     KALBITOR (Takeda Pharmaceuticals America)
FORMULA     C305H442N88O91S8
EXACT_MASS  7049.043
MOL_WEIGHT  7053.828
SEQUENCE    EAMHSFCAFK ADDGPCRAAH PRWFFNIFTR QCEEFIYGGC EGNQNRFESL EECKKMCTRD
            (Disulfide bridge: 7-57, 16-40, 32-53)
  TYPE      Peptide
REMARK      ATC code: B06AC03
            Product: D03931<US>
EFFICACY    Plasma kallikrein inhibitor
  DISEASE   Hereditary angioedema [DS:H01006]
COMMENT     Treatment of hereditary angioedema, Reduction of blood loss during cardiothoracic surgery [plasma kallikrein inhibitor]
TARGET      KLKB1 [HSA:3818] [KO:K01324]
  PATHWAY   hsa04610(3818)  Complement and coagulation cascades
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             B BLOOD AND BLOOD FORMING ORGANS
              B06 OTHER HEMATOLOGICAL AGENTS
               B06A OTHER HEMATOLOGICAL AGENTS
                B06AC Drugs used in hereditary angioedema
                 B06AC03 Ecallantide
                  D03931  Ecallantide (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Angioedema Agents
               Kallikrein Inhibitors
                Ecallantide
                 D03931  Ecallantide (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Serine peptidases
                KLKB1
                 D03931  Ecallantide (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03931
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03931
DBLINKS     CAS: 460738-38-9
            PubChem: 47205919
///
